文献速递核素与放射性配体治疗肿瘤 PET/CT

PSMA靶向放射性配体治疗在肾功能预先受损的转移性去势抵抗性前列腺癌患者中的结局与肾脏安全性

Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function.
PubMed 文献 · Clin Nucl Med · 2024-11-27

本回顾性分析纳入94例肾功能预先受损(GFR≤60 mL/min,相当于CTCAE≥2级)的mCRPC患者,接受[177Lu]Lu-PSMA-617单用或联合[225Ac]Ac-PSMA-617治疗。全队列平均最佳PSA反应为-56.73%±45.71%,67%患者达部分缓解,中位无进展生存期6.7个月、总生存期14.1个月;多数患者CTCAE分级稳定。结论认为PSMA-RLT在该人群中有效且安全,日常临床中不应因肾功能受损而一律排除患者入组。

要点

  • 94例肾功能预先受损(GFR≤60 mL/min,CTCAE≥2级)的mCRPC患者接受PSMA-RLT。
  • 平均最佳PSA反应-56.73%±45.71%,63/94(67%)达部分缓解。
  • 中位无进展生存期6.7个月、总生存期14.1个月;58/94(61.7%)CTCAE分级稳定。

核心结论

  • PSMA-RLT在肾功能预先受损(CTCAE≥2级)的mCRPC患者中是有效且安全的治疗。
  • 日常临床实践中,不应因肾功能受损而一律排除患者入组PSMA-RLT。

研究设计与样本

  • 回顾性分析,纳入94例肾功能预先受损的mCRPC患者,纳入标准为GFR≤60 mL/min(相当于CTCAE≥2级)。
  • 患者接受[177Lu]Lu-PSMA-617单用治疗(n=63)或额外以增强方式联合[225Ac]Ac-PSMA-617治疗(n=31)。
  • 中位给药周期数为4(范围1-16周期),[177Lu]Lu-PSMA-617平均累积活度为29.9±16.3 GBq(范围6.9-87.2 GBq)。
  • 主要关注的血液参数为肌酐、胱抑素C及相应GFR值,GFR变化按CTCAE v5.0分级。

主要发现

  • 全队列平均最佳PSA反应为-56.73%±45.71%,63/94(67%)患者达部分缓解。
  • 中位无进展生存期为6.7个月,中位总生存期为14.1个月。
  • 5/94(5.3%)患者改善至CTCAE 0级,23/94(24.5%)改善至CTCAE 1级。
  • 3/94(3.2%)患者从CTCAE 3级改善至2级,仅5/94(5.3%)患者CTCAE分级下降。
  • 多数患者(58/94,61.7%)CTCAE分级保持稳定。

临床怎么用

  • 作者认为,日常临床实践中不应因肾功能受损而一律排除患者入组PSMA-RLT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to evaluate the outcome and renal safety of prostate-specific membrane antigen (PSMA)-radioligand therapy (RLT) in patients with metastatic castration-resistant prostate carcinoma (mCRPC) and preexisting renal impairment. METHODS: Ninety-four patients with preexisting renal impairment were included in this retrospective analysis. Inclusion criterion was a glomerular filtration rate (GFR) of ≤60 mL/min (equivalent to Common Terminology Criteria of Adverse Events [CTCAE] ≥2). Patients underwent either [ 177 Lu]Lu-PSMA-617 RLT exclusively (n = 63) or additionally in augmented manner with [ 225 Ac]Ac-PSMA-617 (n = 31). The median number of administered cycles was 4 (range, 1-16 cycles) with a mean cumulative activity of 29.9 ± 16.3 GBq (range, 6.9-87.2 GBq) [ 177 Lu]Lu-PSMA-617. Main blood parameters of interest were creatinine, cystatin C, and the respective GFR values. Changes in GFR were categorized according to CTCAE v5.0. RESULTS: In the entire cohort, mean best PSA response was -56.73% ± 45.71%, with 63 of 94 patients (67%) experiencing partial remission. The median progression-free survival and overall survival were 6.7 and 14.1 months, respectively. Under PSMA-RLT, 5 of 94 patients (5.3%) improved to CTCAE grade 0, and 23 of 94 (24.5%) improved to CTCAE grade 1. Three of 94 patients (3.2%) improved from CTCAE grade 3 to grade 2, and only 5 of 94 (5.3%) decreased. The majority (58/94 [61.7%]) of patients stayed stable in terms of CTCAE grading. CONCLUSIONS: PSMA-RLT is an effective and safe treatment in mCRPC patients with preexisting impaired renal function (CTCAE ≥2). In daily clinical practice, patients should not be categorically excluded from enrolment to PSMA-RLT due to renal impairment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bastian MB, Sieben M, Burgard C, et al. Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function. Clin Nucl Med. 2024. PMID: 39601036. doi:10.1097/RLU.0000000000005583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。